Telix Pharmaceuticals (TLX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.27B and a free-cash-flow yield of -2.0%. Over the most recent reported fiscal year, revenue grew 55.6% and free cash flow per share fell 1327.3%. Nama's AI scorecard rates it Sell, 4.1 out of 10. On 12-month momentum it ranks in the middle band of its market.
AI scorecard
Sell · 4.1/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Middle · +12.6% over 12 months ex. last
Middle fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-68.3%
How far the last close sits under the highest price of the past five years.
Market cap
$3.27B
Trailing P/E
—
Price / book
6.7
Price / sales
3.7
FCF yield
-2.0%
Dividend yield
—
Gross margin
47.6%
Operating margin
9.7%
Net margin
3.8%
Revenue growth (YoY)
+55.6%
Revenue growth (3-yr annual)
+94.7%
EPS growth (YoY)
—
FCF/share growth (YoY)
-1327.3%
Beta
0.6
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
TLX analyst price target
Median target $20.59 from 4 analysts, ranging $17.58 – $21.53.
Nama's AI scorecard currently rates Telix Pharmaceuticals Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is the TLX price target?
The median analyst price target from 4 analysts is $20.59, with a range of $17.58 – $21.53.
Is TLX Shariah compliant?
Nama's AAOIFI-style screen reads Telix Pharmaceuticals as Can't Tell. A figure the screen needs is missing, so it can't tell.